Cytokines and inhibitors have an up- or down-regulatory effect on MMP2 expression in mesothelioma, suggesting the clinical value of targeting MMP2 for management of mesothelioma and its pathogenesis [15]. The gene discussed is MMP2; the disease is mesothelioma.